{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:15:19Z","timestamp":1793502919132,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K24AR067847"],"award-info":[{"award-number":["K24AR067847"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["1UL1TR002541-01"],"award-info":[{"award-number":["1UL1TR002541-01"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00198-023-06932-2","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T02:03:56Z","timestamp":1696557836000},"page":"255-263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6755-8469","authenticated-orcid":false,"given":"Sabashini K.","family":"Ramchand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy N.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Sassana-Khadka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savannah","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Z.","family":"Leder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"key":"6932_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6932_CR2","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1210\/jc.2016-1160","volume":"101","author":"JN Tsai","year":"2016","unstructured":"Tsai JN, Uihlein AV, Burnett-Bowie SM, Neer RM, Derrico NP, Lee H, Bouxsein ML, Leder BZ (2016) Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study). J Clin Endocrinol Metab 101:2023\u20132030","journal-title":"J Clin Endocrinol Metab"},{"key":"6932_CR3","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821\u2013831","journal-title":"N Engl J Med"},{"key":"6932_CR4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"6932_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165\u2013176","journal-title":"Cell"},{"key":"6932_CR6","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","volume":"95","author":"H Yasuda","year":"1998","unstructured":"Yasuda H, Shima N, Nakagawa N et al (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL. Proc Natl Acad Sci U S A 95:3597\u20133602","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6932_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Mineral Res 24:153\u2013161","journal-title":"J Bone Mineral Res"},{"key":"6932_CR8","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/jbmr.149","volume":"25","author":"IR Reid","year":"2010","unstructured":"Reid IR, Miller PD, Brown JP et al (2010) Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 25:2256\u20132265","journal-title":"J Bone Miner Res"},{"key":"6932_CR9","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980","journal-title":"J Clin Endocrinol Metab"},{"key":"6932_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J, Amg Bone Loss Study G","year":"2008","unstructured":"Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J, Amg Bone Loss Study G (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222\u2013229","journal-title":"Bone"},{"key":"6932_CR11","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","volume":"28","author":"MR McClung","year":"2017","unstructured":"McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 28:1723\u20131732","journal-title":"Osteoporos Int"},{"key":"6932_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","volume":"29","author":"MB Zanchetta","year":"2018","unstructured":"Zanchetta MB, Boailchuk J, Massari F, Silveira F, Bogado C, Zanchetta JR (2018) Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study. Osteoporos Int 29:41\u201347","journal-title":"Osteoporos Int"},{"key":"6932_CR13","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/jbmr.448","volume":"26","author":"JP Brown","year":"2011","unstructured":"Brown JP, Dempster DW, Ding B, Dent-Acosta R, San Martin J, Grauer A, Wagman RB, Zanchetta J (2011) Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study. J Bone Miner Res 26:2737\u20132744","journal-title":"J Bone Miner Res"},{"key":"6932_CR14","unstructured":"Seeman E ZR, Zanchetta JR, Hanley DA, Wang A, Libanti C, Wagman RB (2017) Bone microarchitecture after discontinuation of denosumab in postmenopausal women with low bone mass. J Bone Miner Res 31:Supplement 1"},{"key":"6932_CR15","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/jbmr.1808","volume":"28","author":"JP Brown","year":"2013","unstructured":"Brown JP, Roux C, Torring O et al (2013) Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res 28:746\u2013752","journal-title":"J Bone Miner Res"},{"key":"6932_CR16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R et al (2018) Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res 33:190\u2013198","journal-title":"J Bone Miner Res"},{"key":"6932_CR17","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","volume":"37","author":"F Cosman","year":"2022","unstructured":"Cosman F, Huang S, McDermott M, Cummings SR (2022) Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses. J Bone Miner Res 37:2112\u20132120","journal-title":"J Bone Miner Res"},{"key":"6932_CR18","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P (2019) Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. J Bone Miner Res 34:2220\u20132228","journal-title":"J Bone Miner Res"},{"key":"6932_CR19","doi-asserted-by":"publisher","first-page":"115478","DOI":"10.1016\/j.bone.2020.115478","volume":"138","author":"P Makras","year":"2020","unstructured":"Makras P, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Anastasilakis AD (2020) The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. Bone 138:115478","journal-title":"Bone"},{"key":"6932_CR20","doi-asserted-by":"crossref","unstructured":"Kendler D, Chines A, Clark P, Ebeling PR, McClung M, Rhee Y, Huang S, Stad RK (2020) Bone mineral density after transitioning from denosumab to alendronate. J Clin Endocrinol Metab\u00a0105(3):e255\u2013e264","DOI":"10.1210\/clinem\/dgz095"},{"key":"6932_CR21","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/jbmr.4259","volume":"36","author":"SK Ramchand","year":"2021","unstructured":"Ramchand SK, David NL, Lee H, Eastell R, Tsai JN, Leder BZ (2021) Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA-HD Study Extension. J Bone Miner Res 36:921\u2013930","journal-title":"J Bone Miner Res"},{"key":"6932_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00223-019-00553-w","volume":"105","author":"AM Horne","year":"2019","unstructured":"Horne AM, Mihov B, Reid IR (2019) Effect of Zoledronate on Bone Loss After Romosozumab\/Denosumab: 2-Year Follow-up. Calcif Tissue Int 105:107\u2013108","journal-title":"Calcif Tissue Int"},{"key":"6932_CR23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","volume":"101","author":"IR Reid","year":"2017","unstructured":"Reid IR, Horne AM, Mihov B, Gamble GD (2017) Bone Loss After Denosumab: Only Partial Protection with Zoledronate. Calcif Tissue Int 101:371\u2013374","journal-title":"Calcif Tissue Int"},{"key":"6932_CR24","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/jbmr.3962","volume":"35","author":"J Everts-Graber","year":"2020","unstructured":"Everts-Graber J, Reichenbach S, Ziswiler HR, Studer U, Lehmann T (2020) A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains. J Bone Miner Res 35:1207\u20131215","journal-title":"J Bone Miner Res"},{"key":"6932_CR25","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","volume":"36","author":"AS Solling","year":"2021","unstructured":"Solling AS, Harslof T, Langdahl B (2021) Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study. J Bone Miner Res 36:1245\u20131254","journal-title":"J Bone Miner Res"},{"key":"6932_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1385\/JCD:4:2:105","volume":"4","author":"SL Bonnick","year":"2001","unstructured":"Bonnick SL, Johnston CC Jr, Kleerekoper M, Lindsay R, Miller P, Sherwood L, Siris E (2001) Importance of precision in bone density measurements. J Clin Densitom 4:105\u2013110","journal-title":"J Clin Densitom"},{"key":"6932_CR27","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.cell.2021.03.010","volume":"184","author":"MM McDonald","year":"2021","unstructured":"McDonald MM, Khoo WH, Ng PY et al (2021) Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell 184:1940","journal-title":"Cell"},{"key":"6932_CR28","doi-asserted-by":"publisher","unstructured":"Fu Q, Bustamante-Gomez NC, Reyes-Pardo H et al (2023) Reduced osteoprotegrin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation. J Clin Invest Insight 8(18):e167790. https:\/\/doi.org\/10.1172\/jci.insight.167790","DOI":"10.1172\/jci.insight.167790"},{"key":"6932_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3389\/fendo.2020.00250","volume":"11","author":"K Jahn-Rickert","year":"2020","unstructured":"Jahn-Rickert K, Wolfel EM, Jobke B, Riedel C, Hellmich M, Werner M, McDonald MM, Busse B (2020) Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation. Front Endocrinol 11:250","journal-title":"Front Endocrinol"},{"key":"6932_CR30","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1210\/jcem.87.3.8325","volume":"87","author":"O Johnell","year":"2002","unstructured":"Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E (2002) Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:985\u2013992","journal-title":"J Clin Endocrinol Metab"},{"key":"6932_CR31","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1359\/jbmr.2002.17.2.341","volume":"17","author":"SM Ott","year":"2002","unstructured":"Ott SM, Oleksik A, Lu Y, Harper K, Lips P (2002) Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. J Bone Miner Res 17:341\u2013348","journal-title":"J Bone Miner Res"},{"key":"6932_CR32","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00198-022-06388-w","volume":"33","author":"J Ha","year":"2022","unstructured":"Ha J, Kim J, Jeong C, Lim Y, Kim MK, Kwon HS, Song KH, Kang MI, Baek KH (2022) Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women. Osteoporos Int 33:1591\u20131599","journal-title":"Osteoporos Int"},{"key":"6932_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00223-022-00962-4","volume":"111","author":"N Hong","year":"2022","unstructured":"Hong N, Shin S, Lee S, Kim KJ, Rhee Y (2022) Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis. Calcif Tissue Int 111:47\u201355","journal-title":"Calcif Tissue Int"},{"key":"6932_CR34","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.4065\/77.10.1044","volume":"77","author":"S Greenspan","year":"2002","unstructured":"Greenspan S, Field-Munves E, Tonino R, Smith M, Petruschke R, Wang L, Yates J, de Papp AE, Palmisano J (2002) Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 77:1044\u20131052","journal-title":"Mayo Clin Proc"},{"key":"6932_CR35","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"6932_CR36","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut 3rd","year":"2004","unstructured":"Chesnut CH 3rd, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"6932_CR37","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"6932_CR38","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/jbmr.2565","volume":"30","author":"S Jha","year":"2015","unstructured":"Jha S, Wang Z, Laucis N, Bhattacharyya T (2015) Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996\u20132012: An Ecological Analysis. J Bone Miner Res 30:2179\u20132187","journal-title":"J Bone Miner Res"},{"key":"6932_CR39","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1056\/NEJMcp1513724","volume":"374","author":"DM Black","year":"2016","unstructured":"Black DM, Rosen CJ (2016) Postmenopausal Osteoporosis. N Engl J Med 374:2096\u20132097","journal-title":"N Engl J Med"},{"key":"6932_CR40","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637\u2013645","journal-title":"JAMA"},{"key":"6932_CR41","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1093\/jnci\/djh319","volume":"96","author":"S Martino","year":"2004","unstructured":"Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR, Investigators C (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751\u20131761","journal-title":"J Natl Cancer Inst"},{"key":"6932_CR42","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bone.2014.01.009","volume":"61","author":"MA Gallant","year":"2014","unstructured":"Gallant MA, Brown DM, Hammond M, Wallace JM, Du J, Deymier-Black AC, Almer JD, Stock SR, Allen MR, Burr DB (2014) Bone cell-independent benefits of raloxifene on the skeleton: a novel mechanism for improving bone material properties. Bone 61:191\u2013200","journal-title":"Bone"}],"updated-by":[{"DOI":"10.1007\/s00198-023-06966-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000}}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06932-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-023-06932-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06932-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T09:02:49Z","timestamp":1706864569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-023-06932-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6932"],"URL":"https:\/\/doi.org\/10.1007\/s00198-023-06932-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00198-023-06966-6","asserted-by":"object"}]},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,6]]},"assertion":[{"value":"27 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00198-023-06966-6","URL":"https:\/\/doi.org\/10.1007\/s00198-023-06966-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JNT has a financial interest in Amgen. JNT\u2019s interests were reviewed and are managed by MGH and Mass General Brigham in accordance with their conflict-of-interest policies. All other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}